Psilocybin for Stroke
(PHATHOM Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of the current studies is to evaluate the safety and tolerability of psilocybin in patients with chronic stroke.
Who Is on the Research Team?
Victor Urrutia, M.D.
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
This trial is for adults over 18 who had a stroke confirmed by CT or MRI at least a year ago. Participants must understand the study, agree not to start new meds without approval, avoid certain supplements and nonprescription drugs, follow dietary restrictions before dosing, have transportation arranged post-treatment, and provide emergency contact details.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Psilocybin
Trial Overview
The trial is testing the safety and tolerability of psilocybin from Usona Institute in patients with chronic stroke. It aims to see how well these individuals can handle the drug as an adjunct therapy alongside their standard treatment regimen.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive 25 mg of psilocybin
Participants will receive 12.5 mg of psilocybin followed by another 12.5 mg of psilocybin 2 hours after the first dose.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Rose Hill
Collaborator
Usona Institute
Collaborator
University of California, Berkeley
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.